Lamotrigine administration in panic disorder with agoraphobia

Clinical Neuropharmacology

Volumn 33, Issue 3, 2010, Pages 126-128

  Masdrakis, Vasilios G ^a   Papadimitriou, George N ^a   Oulis, Panagiotis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Agoraphobia; Anticonvulsant drugs; Lamotrigine; Panic disorder

Indexed keywords

ALPRAZOLAM; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; LAMOTRIGINE; PAROXETINE;

ADJUVANT THERAPY; ADULT; AGORAPHOBIA; ARTICLE; CASE REPORT; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MONOTHERAPY; PANIC; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR;

ADULT; AGORAPHOBIA; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 77953158845     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181d4c1f6     Document Type: Article

References (22)

1. Gorman JM, Kent JM, Sullivan GM, et al. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505.
2. Van Ameringen M, Mancini C, Pipe B, et al. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004;64:2199-2220.
3. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders. A critical review of the evidence. J Clin Psychopharmacol 2007;27:263-272.
4. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994;55:134-136.
5. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-471.
6. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed flexible dose study. J Clin Psychiatry 2006;67:1573-1576.
7. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007;113:165-183.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Ed 4th, text revision. Washington, DC: American Psychiatric Association; 2000.
9. Sheehan D, Lecrubier Y, Sheehan KH, et al. The Mini International Neuropsychiatric Interview (M. I. N. I.). The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;(suppl 20):22-33.
10. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
11. Chambless DL, Caputo GC, Bright P, et al. Assessment of fear of fear in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. J Consult Clin Psychol 1984;52:1090-1097.
12. Chambless DL, Caputo GC, Jasin SE, et al. The Mobility Inventory for agoraphobia. Behav Res Ther 1985;23:35-44.
13. Guy W, ed. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology, Rev. Ed. Washington, DC: US Department of Health, Education and Welfare, National Institute of Mental Health; 1976:217-222.
14. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders-first revision. World J Biol Psychiatry 2008;9:248-312.
15. McHugh RK, Smits JA, Otto MW. Empirically supported treatments for panic disorder. Psychiatr Clin North Am 2009;32:593-610.
16. McHugh RK, Otto MW, Barlow DH, et al. Cost-efficacy of individual and combined treatments for panic disorder. J Clin Psychiatry 2007;68:1038-1044.
17. Landon TM, Barlow DH. Cognitive-behavioral treatment for panic disorder: current status. J Psychiatr Pract 2004;10:211-226.
18. Slaap BR, den Boer JA. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress Anxiety 2001;14:112-122.
19. Bakker A, van Balkom AJLM, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol 2005;8:473-482.
20. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999;45:1226-1229.
21. Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000;34:527-528
22. Uzun O. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J Psychopharmacol 2008; doi: 10.1177/0269881108098809.